Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures. Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.
Price analytics
Returns
1 day
5.9%
1 week
0.0%
1 month
0.0%
3 months
-25.0%
6 months
-43.7%
1 year
-67.9%
3 years
-67.3%
Risk
Volatility (1y ann.)
90.0%
Beta vs ASX 200
1.35
Sharpe (1y)
-0.84
VaR 95% (1-day)
-8.9%
Max drawdown (1y)
-81.7%
Off 1-year high
-78.0%
Technicals
RSI(14)
50
vs 50DMA
5.9%
vs 200DMA
-41.8%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value97.9
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
89
Growth100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum18.5
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
80
Position in 52-week range
8
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).